Page 14 - Thomas Theuringer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) Q1 2021 net sales rise 52% (48% CER) to $567.2 million, exceeds outlook for at least 45% CER growth; adj. EPS up 94% to $0.66 ($0.65 CER), exceeds outlook for ~$0.60-0.62 CER 16% CER growth to $364 million from non-COVID product groups, represent 64% of total sales, while COVID-19 product group sales rise 186% CER to $203 million Q1 2021 operating cash flow rises over 700% to $128.6 million, free cash flow of $82.3 million Reaffirming full-year 2021 outlook for ~18-20% CER net sales growth and ~$2.42-2.46 CER adjusted diluted EPS QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)...

QIAGEN N.V.: QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and Diagnostics Building on the success of EZ1 technology, three versions offer application area tailored value Integration with QIAsphere digital infrastructure allows for optimized lab productivity QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the upcoming launch of the EZ2 Connect product line, a next-level automated sample-processing platform whose simplicity, flexibility and speed will benefit biomedical research, forensics and clinical diagnostics. T...

Message : Required fields DIASORIN, IN PARTNERSHIP WITH QIAGEN, LAUNCHES THE NEW LIAISON® LYMEDETECT® ASSAY BASED ON QUANTIFERON TECHNOLOGY IN COUNTRIES ACCEPTING CE MARK FOR EARLY DIAGNOSIS OF LYME BORRELIOSIS THE LIAISON® LYMEDETECT® ASSAY IS A SOLUTION FOR THE EARLY DIAGNOSIS OF LYME BORRELIOSIS COMBINING DETECTION OF IGG AND IGM ANTIBODIES AND CELLULAR IMMUNITY THE TEST IS AVAILABLE IN COUNTRIES ACCEPTING THE CE MARK AND IS DESIGNED TO BE RUN ON THE LIAISON® XL AND LIAISON® XS PLATFORMS IN CLINICAL STUDIES, THE ASSAY SHOWED, WITHIN 21 DAYS FROM ...

QIAGEN N.V.: QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity CE-IVD marking for Europe and other countries worldwide, EUA (Emergency Use Application) submission made in the U.S. Streamlined workflow cuts costs and plastic usage offering time to result of about two hours QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the artus SARS-CoV-2 Prep&Amp UM Kit which uses a liquid based sample preparation technology to simplify and increase COVID-19 testing throughput. The artus SARS-CoV-2 P...

QIAGEN N.V.: QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance Kit supports analysis of over 6,000 samples simultaneously on highest-throughput sequencers Integrates with QIAGEN Digital Insights cloud solutions to support variant detection and reporting including clade and lineage annotations across sequencing platforms QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the launch of QIAseq DIRECT SARS-CoV-2 Kit, a viral genome enrichment and library preparation solution that significantly reduces library turn...